Last reviewed · How we verify

Neisseria meningitidis meningitis — Treatment Landscape & Competitive Intelligence

Neisseria meningitidis meningitis (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Neisseria meningitidis meningitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Merrem Meropenem Pfizer meropenem 1996-01-01
Merrem Merrem National Institutes of Health Clinical Center (CC) Beta-lactamase, Beta-lactamase NDM-1, Beta-lactamase class B VIM-2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. National Institutes of Health Clinical Center (CC) · 1 drug in Neisseria meningitidis meningitis
  2. Pfizer · 1 drug in Neisseria meningitidis meningitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Neisseria meningitidis meningitis:

Cite this brief

Drug Landscape (2026). Neisseria meningitidis meningitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/neisseria-meningitidis-meningitis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing